These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29637799)

  • 1. Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection.
    Wessels U; Zadak M; Reiser A; Brockhaus J; Ritter M; Abdolzade-Bavil A; Heinrich J; Stubenrauch K
    Bioanalysis; 2018 Jun; 10(11):803-814. PubMed ID: 29637799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Observations of Systemic and Ocular Antidrug Antibody Response to Intravitreally Administered Drugs.
    Wessels U; Zadak M; Weidmann AM; Stuchly T; Stubenrauch KG
    AAPS J; 2022 Nov; 25(1):2. PubMed ID: 36414857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.
    Wessels U; Schick E; Ritter M; Kowalewsky F; Heinrich J; Stubenrauch K
    Bioanalysis; 2017 Jun; 9(11):849-859. PubMed ID: 28517957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I.
    Wessels U; Poehler A; Moheysen-Zadeh M; Zadak M; Staack RF; Umana P; Heinrich J; Stubenrauch K
    Bioanalysis; 2016 Oct; 8(20):2135-45. PubMed ID: 27582032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
    Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
    J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
    Pierog P; Krishna M; Yamniuk A; Chauhan A; DeSilva B
    J Immunol Methods; 2015 Jan; 416():124-36. PubMed ID: 25462536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.
    Adedokun OJ; Gunn GR; Leu JH; Gargano C; Xu Z; Sandborn WJ; Rutgeerts P; Shankar G
    Inflamm Bowel Dis; 2019 Aug; 25(9):1532-1540. PubMed ID: 30753466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity screening assay development for a novel human-mouse chimeric anti-CD147 monoclonal antibody (Metuzumab).
    Mi L; Li W; Li M; Chen T; Wang M; Sun L; Chen Z
    J Immunol Methods; 2016 Jun; 433():38-43. PubMed ID: 26944771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
    Li J; Schantz A; Schwegler M; Shankar G
    J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.
    Bloem K; Hernández-Breijo B; Martínez-Feito A; Rispens T
    Ther Drug Monit; 2017 Aug; 39(4):327-332. PubMed ID: 28463887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA.
    Smith HW; Butterfield A; Sun D
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):230-7. PubMed ID: 17869396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies.
    Sloan JH; Conway RG; Pottanat TG; Troutt JS; Higgs RE; Konrad RJ; Qian YW
    Bioanalysis; 2016 Oct; 8(20):2157-68. PubMed ID: 27593891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of drug interference in immunogenicity assays.
    Hart MH; de Vrieze H; Wouters D; Wolbink GJ; Killestein J; de Groot ER; Aarden LA; Rispens T
    J Immunol Methods; 2011 Sep; 372(1-2):196-203. PubMed ID: 21824477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope characterization of the ADA response directed against a targeted immunocytokine.
    Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
    J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference.
    Weeraratne DK; Lofgren J; Dinnogen S; Swanson SJ; Zhong ZD
    J Immunol Methods; 2013 Oct; 396(1-2):44-55. PubMed ID: 23933325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.
    Yu DA; You M; Ji WW; Lu Y; Liu B; Yan SS
    Toxicol Lett; 2018 Aug; 292():73-77. PubMed ID: 29709424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays.
    Zoghbi J; Xu Y; Grabert R; Theobald V; Richards S
    J Immunol Methods; 2015 Nov; 426():62-9. PubMed ID: 26255760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ionic strength dissociation assay (HISDA) for high drug tolerant immunogenicity testing.
    Jordan G; Pöhler A; Guilhot F; Zaspel M; Staack RF
    Bioanalysis; 2020 Jun; 12(12):857-866. PubMed ID: 32603603
    [No Abstract]   [Full Text] [Related]  

  • 20. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.